VIE

Inebilizumab-cdon (Anti-CD19 mAb)

Myasthenia Gravis

Phase 3 (Data)

Exp Date

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Inebilizumab-cdon (Anti-CD19 mAb) in Myasthenia Gravis

  • ClinicalTrials.gov (NCT04524273): Myasthenia Gravis Inebilizumab Trial (MINT)


WHAT IS THE CATALYST EVENT?

  • Phase 3 Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBA


PRIOR DATA/EVENTS

PRESS RELEASE

Updated by HC

VIE, Inebilizumab-cdon (Anti-CD19 mAb), Myasthenia Gravis, neuromuscular disorder that causes weakness in the skeletal muscles,

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon